Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Bristol Myers Squibb Agreed To Acquire Orbital Therapeutics, A Privately Held Biotechnology For $1.5B

Author: Benzinga Newsdesk | October 10, 2025 06:02am

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Transaction further strengthens BMS's industry-leading cell therapy portfolio, expanding CAR T-cell access to more patients in the future

Posted In: BMY